Investigational^↗Metabolic^↗

Survodutide^↗

Related names in cited records: BI 456906^↗

A glucagon/GLP-1 receptor agonist candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.^↗

Citation markers ↗ open the public records supporting the adjacent statements.

Profile update · July 27, 2026

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change. ¹

This version supersedes public version 1.

Evidence summary

What the cited records say

ClinicalTrials.gov lists a Boehringer Ingelheim study as active, not recruiting, updated July 22, 2026.^↗

This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.

Cited context

Dated source history

July 22, 2026
Clinical trials
Survodutide liver-activity study record updated^↗
ClinicalTrials.gov lists an active, not recruiting Survodutide study sponsored by Boehringer Ingelheim.^↗